These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33830971)

  • 41. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
    Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
    Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
    [No Abstract]   [Full Text] [Related]  

  • 42. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Kajiura S; Hosokawa A; Nanjyo S; Nakada N; Ando T; Sugiyama T
    Nihon Shokakibyo Gakkai Zasshi; 2016 Apr; 113(4):655-61. PubMed ID: 27052395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastrointestinal stromal tumours.
    Blay JY; Kang YK; Nishida T; von Mehren M
    Nat Rev Dis Primers; 2021 Mar; 7(1):22. PubMed ID: 33737510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
    Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade.
    Serrano C; George S
    Clin Cancer Res; 2020 Oct; 26(19):5078-5085. PubMed ID: 32601076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.
    Cioffi A; Maki RG
    J Clin Oncol; 2015 Jun; 33(16):1849-54. PubMed ID: 25918303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Gastrointestinal stromal tumors (GIST): The particularities aspects in African countries].
    Togo A; Traoré A; Dembélé BT; Diakité I; Traoré A; Konaté M; Bah A; Kanté L; Koné T; Dicko MY; Yoro Sidibé B; Ahmadou I; Diallo G
    Bull Cancer; 2018 Feb; 105(2):212-213. PubMed ID: 29397915
    [No Abstract]   [Full Text] [Related]  

  • 54. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
    Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal stromal tumor - A review of clinical studies.
    Khoshnood A
    J Oncol Pharm Pract; 2019 Sep; 25(6):1473-1485. PubMed ID: 31068088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Reichardt P
    Oncol Res Treat; 2018; 41(7-8):472-477. PubMed ID: 29895025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
    Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ; Reid TR
    J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.